Last updated: February 14, 2026
Overview
NDC 00121-0873 is identified as Bemarsen (arsenic trioxide), a chemotherapeutic agent primarily used for treating acute promyelocytic leukemia (APL). The drug's market presence is influenced by evolving treatment protocols, patent status, and manufacturing competition. This analysis synthesizes current market dynamics, pricing trends, regulatory factors, and future projections.
Current Market Landscape
-
Indications: NDC 00121-0873 is approved for APL, a subtype of acute myeloid leukemia. The drug functions by inducing apoptosis in malignant promyelocytes through arsenic trioxide's pro-oxidant activity.
-
Market Players: Major suppliers include Teva Pharmaceuticals and Sun Pharmaceutical Industries. Generic versions have entered markets following patent expirations, expanding access and impacting pricing.
-
Market Size: The global leukemia drug market was valued at $6.2 billion in 2022, with arsenic trioxide representing approximately 7% of this segment, roughly $434 million (based on market share estimates). The APL-specific segment is smaller but growing, driven by increased diagnosis and treatment standardization.
-
Competitive Dynamics: Advances in targeted therapies and combination treatments influence arsenic trioxide utilization. Cost-effective generics have eroded branded pricing margins.
Pricing Trends
-
List Price: The average wholesale price (AWP) for brand-name arsenic trioxide injections is approximately $2,000 per 10 mg vial. Generic prices hover near $400–$1,000 per vial, reflecting aggressive price competition.
-
Historical Trends: From 2018 to 2022, prices declined approximately 35% due to patent expirations and increased generic entry.
-
Reimbursement: Insurance reimbursement aligns closely with AWP; however, patient co-pays vary based on formulary coverage, influencing market penetration.
Regulatory & Patent Considerations
-
Patent Status: The original patents for arsenic trioxide expired around 2015; subsequent patent challenges and exclusivity extensions have impacted market competition.
-
Regulatory Pathways: Both the FDA and EMA approve arsenic trioxide for clinical use; ongoing investigations for new indications or formulations could influence future utilization.
-
Orphan Drug Designation: APL's status as a rare disease ensures certain exclusivity rights, but this has limited impact given the drug's age and patent expiration.
Future Price Projections (2023–2028)
| Year |
Estimated Price Range per Vial |
Factors Influencing Price |
| 2023 |
$400 – $1,000 |
Increased generic competition, price erosion plateauing |
| 2024 |
$350 – $900 |
Market stabilization, potential generic price reductions |
| 2025 |
$300 – $800 |
Continued competition, healthcare cost pressures |
| 2026 |
$300 – $750 |
Regulatory approvals for biosimilars, potential new indications |
| 2027 |
$250 – $700 |
Market saturation, biosimilar entry |
| 2028 |
$250 – $650 |
Cost-control policies, market maturation |
Factors Affecting Price Dynamics
-
Generic Market Penetration: Greater accessibility broadly drives down prices. As of 2023, generics constitute 85% of units sold, with branded versions cyclically maintaining a niche segment.
-
Healthcare Policy: Price controls, value-based reimbursement models, and drug affordability initiatives will further reduce prices over time.
-
Technological Advances & New Therapeutics: Competing agents or newer targeted therapies could displace arsenic trioxide, pressuring prices downward.
Key Takeaways
-
The drug's market is predominantly driven by generics, leading to significant price reductions since patent expiration.
-
Continued competition and healthcare policy shifts project a downward trend, with prices settling between $250 and $700 per vial by 2028.
-
The market size remains constrained by the niche indication and competition from newer therapies, limiting revenue growth potential.
FAQs
1. What factors most influence the price of arsenic trioxide?
Market competition from generics, reimbursement policies, and clinical demand significantly influence pricing.
2. How does the expiration of patents affect market pricing?
Patent expiry enables generic manufacturing, increasing supply and reducing prices.
3. Are there upcoming formulations or indications that could impact the market?
Potential developments include biosimilars and new combination therapies, which may alter demand and pricing.
4. How do reimbursement policies influence the drug's profitability?
Reimbursement at or below AWP caps profit margins for suppliers and can limit price flexibility.
5. What are the main risks to price stability?
Introduction of alternative therapies, regulatory changes, and healthcare cost containment measures pose risks to stable pricing.
References
- IQVIA Sales Data (2022)
- FDA Drug Database (2023)
- MarketWatch Reports, Leukemia Treatment Market Analysis (2022)
- Pharmaceutical Commerce, Patent and Market Entry Timelines (2021)
- CMS Pricing and Reimbursement Policies (2023)
